12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FIAsp: Phase I data

Novo Nordisk disclosed in its 2Q13 earnings that a double-blind, crossover, U.S. Phase I trial in 42 Type I diabetics showed that continuous subcutaneous infusion of FIAsp via pump for 14...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >